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Crohn disease (CD), an inﬂammatory bowel disease, is a multifactorial trait with the highest frequency in Ashkenazi
Jewish (AJ) individuals of Central European origin. Recently, three common predisposing CARD15 mutations
(R702W, G908R, and 1007fs) and a polymorphism (P268S) were identiﬁed. To determine whether CARD15
mutations account for the higher prevalence of CD in AJ individuals, the haplotypes and allele frequencies of the
common mutations and variants were assessed in 219 members of 50 AJ and 53 members of 10 Sephardi/Oriental
Jewish (SOJ) multiplex families with CD, in 36 AJ patients with sporadic CD, and in 246 AJ and 82 SOJ controls.
A higher frequency of CARD15 mutations was found in AJ patients from multiplex families with CD from Central
(44.0%) versus Eastern (24.0%) Europe, especially for G908R and 1007fs, and in SOJ patients (34.5%) compared
with AJ (10.1%) or SOJ (5.4%) controls. Contrary to expectation, the frequency of the common mutations was
slightly lower in AJ patients with CD (30.1%) than in SOJ patients with CD (34.5%). The 702W allele was
associated with both the P268 and 268S alleles. CARD15 mutation frequencies were greater in affected sib pairs
than in sporadic CD cases but actually decreased in families with three or more affected sibs, raising the possibility
of genetic heterogeneity. Similarly, our linkage evidence on chromosome 16 was diminished in the families with
three or more affected sibs compared with sib pairs. Screening the CARD15 gene for rare variants revealed ﬁve
novel changes (D113N, D357A, I363F, L550V, and N852S) of which N852S occurred only in AJ individuals and
may be disease predisposing. Also, there was no evidence for increased risk associated with the recently described
IVS+158 single-nucleotide polymorphism. Although the AJ controls appear to have a higher frequency of CARD15
mutations than the SOJ controls, it is unlikely that this difference fully explains the excess frequency of CD in the
AJ population.
Introduction
Crohn disease (CD [MIM 266600]) is an inﬂammatory
bowel disease resulting from defects in mucosal immunity
and intestinal epithelial barrier function (Yang et al. 2001;
Podolsky 2002; Swidsinski et al. 2002). On the basis of
familial aggregation, twin, and spouse studies, it has been
determined that disease susceptibility is inherited as amul-
tifactorial trait (King et al. 1992; Binder 1998; Ahmad et
al. 2001). It is of relevance that CD primarily affectswhite
individuals, with the highest prevalence among individ-
uals of Ashkenazi Jewish (AJ) descent, occurring two to
four times more frequently than in non-Jewish white pop-
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ulations (Roth et al. 1989a, 1989b; Kurata et al. 1992;
Yang et al. 2001). Among Jews, the prevalence of CD in
the Ashkenazim is higher than in Sephardic or Oriental
Jews (SOJ) (Yang et al. 1993), and, even among the Ash-
kenazim, those of Central European origin have a rela-
tively higher risk for CD than those of Polish and Russian
origin (Roth et al. 1989a, 1989b; Zlotogora et al. 1990;
Yang et al. 1993). Although the basis for the increased
frequency of CD in AJ individuals is not known, it could
be hypothesized that they have a higher frequency of mu-
tations in predisposing genes.
Recently, several groups performed genomewide
scans that identiﬁed chromosomal regions containing
potential predisposing genes for CD, including IBD1
(16q12) (Hugot et al. 1996), IBD2 (12q13.2) (Duerr et
al. 1998), IBD3 (6q21 [major histocompatibility com-
plex]) (Hampe et al. 1999a, 1999b), IBD4 (14q11-12)
(Ma et al. 1999), and IBD5 (5q31-33) (Rioux et al.
2000, 2001), as well as regions on 1p, 3q, 4q (Cho et
al. 1998), and 19p13 (Rioux et al. 2000). Subsequently,
three groups independently identiﬁed the IBD1 suscep-
tibility gene on chromosome 16 as the CARD15 (also
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known as “NOD2”) gene (Hampe et al. 2001; Hugot
et al. 2001; Ogura et al. 2001). The LRR domain of
the gene has a binding activity for bacterial peptido-
glycans, and mutations in this domain abrogate nucle-
ar factor-kB–mediated signaling (Inohara et al. 1999,
2000; Chamaillard et al. 2002).
Studies of European and North American families
with CD identiﬁed three common CARD15 mutations,
R702W, G908R, and 1007fs, and a polymorphism,
P268S, that was always found with the mutant alleles
(Hampe et al. 2001; Hugot et al. 2001; Ogura et al.
2001). The frequencies of the mutant alleles in white
patients with CD were 3.5%–12.9% for R702W, 0.8%–
6.0% for G908R, and 1.7%–13.7% for 1007fs, with the
lower frequencies found in Norwegian patients (Hampe
et al. 2001). Overall, the frequency for the three muta-
tions in North American and Central and Western Eu-
ropean patients with CD was 19.1%–29.0% (Ahmad et
al. 2001; Hampe et al. 2001; Hugot et al. 2001; Ogura
et al. 2001; Cuthbert et al. 2002; Lesage et al. 2002;
Vermeire et al. 2002). In contrast, studies revealed a low
frequency (2.6%) in African American patients (Bonen
et al. 2002) and an absence of thesemutations in Japanese
(Inoue et al. 2002; Yamazaki et al. 2002) and Korean
patients with CD (Croucher et al. 2003).
Further, studies of the CARD15 alleles from patients
with familial CD by denaturing high-performance liq-
uid chromatography (DHPLC) heteroduplex analysis
and sequencing revealed additional CARD15 polymor-
phisms and rare variants that may be disease causing
(Lesage et al. 2002). The Lesage et al. (2002) study
indicated that 49% of the patients with familial CD had
one (32%) or two (17%) mutant CARD15 alleles.Most
(93%) CARD15 mutations were in the distal third of
the gene, with the three common mutations (R702W,
G908R, and 1007fs) accounting for 81% of identiﬁed
variants.
Although the prevalence of CD is highest in the AJ
population, limited information is available on the nature
and frequency of the common—and, particularly, the
rare—CARD15 mutations in AJ patients with familial
and sporadic CD (Zhou et al. 2002; Sugimura et al.
2003), and no data have been reported for SOJ patients
with CD. In this article, we report the haplotypes and
allele frequencies of the common CARD15 mutations in
50 AJ and 10 SOJ multiplex families with CD, as well
as the allele frequencies in AJ patients with sporadic CD
and in unrelated AJ and SOJ healthy controls. In addi-
tion, we used DHPLC screening and genomic sequencing
to identify ﬁve novel CARD15 lesions and several pre-
viously reported variants. It is notable that the novel
conserved variant, N852S, was found in 15% of the AJ
families with CD and in none of the SOJ families with
CD. Importantly, 32% and 30% of the AJ and SOJ fam-
ilies with CD, respectively, did not have a CARD15 mu-
tation, indicating the heterogeneity of the predisposing
genes causing CD among Jewish patients.
Subjects and Methods
Patients
Fifty AJ multiplex families with CD were recruited
from the New York metropolitan area and Israel, in-
cluding 115 patients, 79 unaffected parents, and 25 un-
affected sibs. In Israel, 10 SOJ multiplex families with
CD were recruited, including 21 patients and 32 unaf-
fected ﬁrst-degree relatives. The SOJ CD groupwas com-
posed of ﬁve Sephardic families of Moroccan ( ),np 3
Turkish ( ), and Tunisian ( ) descent and ﬁvenp 1 np 1
Oriental families of Iraqi ( ), Kurdish ( ), Ye-np 1 np 1
meni ( ), Iranian ( ), and Syrian ( ) an-np 1 np 1 np 1
cestry. The multiplex family groups contained single sib-
ships with at least two affected sibs, except for six AJ
families that contained affected individuals in more than
one sibship. In addition, 36 AJ patients with sporadic
CD andwith no family history of an inﬂammatory bowel
disease participated in this study. All patients with CD
were seen by gastroenterologists, and diagnoses were
based on clinical, endoscopic, radiological, and/or his-
topathological ﬁndings (Lennard-Jones 1989). Families
with a relative affected with ulcerative colitis or inde-
terminate colitis were excluded. All patients completed
a questionnaire requesting demographic and medical in-
formation. Blood specimens were obtained from the pa-
tients with CD and their family members, as well as from
246 unrelated healthy AJ adults from New York and
Israel and from 82 unrelated healthy Israeli SOJ adults.
The healthy SOJ adults were equally of Sephardi and
Oriental (Mediterranean) origin. The study was ap-
proved by the respective institutional review boards, and
informed consent was obtained from each participant.
CARD15 Mutation Detection Strategy
Initially, the haplotypes for the IBD1 locus on chro-
mosome 16q12 were established in each member of the
multiplex families through use of the closely linked mi-
crosatellite markers D16S3035 and D16S3136 and the
P268S CARD15 polymorphism. These haplotypes were
used to determine phase and to calculate haplotype fre-
quencies. The CARD15 P268S polymorphism and the
common mutations R702W, G908R, and 1007fs were
determined in all family members, patients with sporadic
CD, and unrelated healthy individuals. DHPLC analysis
and sequencing were performed in patients who had
none or only one of the three common mutant alleles,
to detect other CARD15 variants, as well as in 188
randomly chosen individuals of the 246 unrelated AJ
healthy controls. The occurrence of these variants was
assessed in all of the family members and in the re-
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Table 1
PCR Primers for Ampliﬁcation, Restriction Analysis, and Sequencing of the CARD15 Mutations and Polymorphisms
MUTATION
RESTRICTION
ENZYME
PRIMERa
PCR OR RESTRICTION
FRAGMENT SIZE
(bp)
Forward Reverse Wild Type Mutant
R702W MspI CTTCCTGGCAGGGCTGTTGTC CATGCACGCTCTTGGCCTCAC 76542422 1302422
G908Rb HhaIb AAGTCTGTAATGTAAAGCCACb CCCAGCTCCTCCCTCTTCb 380 242138
1007fs NlaIV CCTGCAGTCTCTTTAACTGG CTTACCAGACTTCCAGGATG 168 12840
P268S BamHI TGCCTCTTCTTCTGCCTTCCb AGTAGAGTCCGCACAGAGAGb 422 247175
M863V NcoI CTGTTTGCATGATGGGGGGb GGGAGATCACAGCATTAGAGb 212160 372
N852S AluI CTGTTTGCATGATGGGGGGb CAGCCGTCAGTCAATTTGTAG 151 12922
IVS8158 XhoI TGCAGTTTTCTTGGGGAGAT TGTACCTGATCCAGCCCAAT 12595 220
L248R MspI TGCCTCTTCTTCTGCCTTCCb AGTAGAGTCCGCACAGAGAGb 44375 44117258
A612T XcmI ATGTGCTGCTACGTGTTCTCb CAGACACCAGCGGGCACAGb 456 155301
Sequencing primers for promoter region TGTGGTCTCAGGAAGGAAGG ACTGGTGAGCCTGGATCTGT 918 …
Wild Type Mutant
D113Nc AGCCCAGGCCGACAGCCA AGCCCAGGCCAACAGCCA … …
I363Fc GTTGGTCAAGAAGACATCTTC GTTGGTCAAGAAGACTTCTTC … …
L550Vc ACCCTCCTGCACCTGGGCA ACCCTCCTGCACGTGGGCA … …
a Modiﬁed (or, in the case of dot-blot probes, mutated) bases are underlined.
b PCR primers and/or conditions according to or modiﬁed from Lesage et al. (2002).
c Dot-blot probe.
mainder of the unrelated healthy AJ and SOJ individuals
by sequencing or restriction analyses. In addition, the
presence of the IVS8158 polymorphism (Sugimura et al.
2003) was determined in all family members, patients
with sporadic disease, and unrelated healthy controls.
Detection of the CARD15 Common Variants
The common CARD15 mutations (R702W, G908R,
and 1007fs) and the P268S polymorphism were detected
by restriction analyses. The speciﬁc PCR primers and the
size of the restriction fragments before and after diges-
tion are given in table 1. Since the R702W mutation
abolished the restriction site forMspI, the samples found
positive for this mutation by restriction analysis were
sequenced to conﬁrm the correct base change.
DHPLC Analysis
CARD15 exons 2–12 and adjacent intronic sequences
were ampliﬁed individually, with the exception of the
∼1.8-kb exon 4, which was ampliﬁed in ﬁve overlapping
fragments, as described elsewhere (Lesage et al. 2002).
Amplicons were analyzed by DHPLC using the WAVE
System (Transgenomic). Amplicons with abnormal pro-
ﬁles were sequenced.
DNA Sequencing
The promoter region (300 bp to the 10th bp of exon
1) and exons 2–12 and adjacent ﬂanking intronic se-
quences of the CARD15 gene were sequenced using
primers indicated in table 1 or those described elsewhere
(Lesage et al. 2002).
Screening the Control Group for Common and Rare
Mutations/Sequence Variants
The three common mutations (R702W, G908R, and
1007fs); the N852S variant; the P268S, M863V, and
IVS8158 polymorphisms; and the rare L248R and
A612T variants were screened by restriction analysis
(table 1). The D357A, E441K, R703C, and A918D var-
iants were screened by DHPLC, and their altered proﬁles
were conﬁrmed by sequencing. Screening for the newly
identiﬁed variants D113N, I363F, and L550S was per-
formed by dot-blot analyses (Edelmann et al. 2002). (See
the supplemental data in the appendix [online-only] for
details of the laboratory methods used.)
Analysis of Haplotype Frequencies
The ﬁrst stage of analysis was to calculate haplotype
frequencies for the nine haplotypes depicted in ﬁgure 1
within the ﬁve groups deﬁned above. For the nine listed
haplotypes, all 45 possible pairwise combinations can be
discriminated from genotype data, except for the com-
binations AB and CH. For the AJ control group, six in-
dividuals were either AB or CH; in this case, the haplotype
frequencies were determined using gene counting (the ex-
pectation-maximization algorithm) to obtain maximum-
likelihood estimates. Similarly, gene counting was used
for the AJ sporadic affected group, in which two individ-
uals were either AB or CH. For the AJ multiplex sample
and the SOJ multiplex sample, chromosomes were clus-
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Figure 1 Haplotypes in the AJ and SOJ patients with CD
tered into two groups: a control group, which contained
independent chromosomes not carried by any affected
individual in the pedigree ( for the AJ sample andnp 52
for SOJ sample), and an affected group, whichnp 8
contained independent chromosomes carried by at least
one affected individual in the pedigree ( for AJnp 138
sample and for SOJ sample). In the SOJmultiplexnp 32
families with CD, all parents were genotyped or could be
reconstructed from unaffected sibs. In the AJ multiplex
families, some parents weremissing genotype information
and could not be reconstructed from unaffected sibs. This
and subsequent analyses focused only on chromosomes
directly observed or reconstructed from unaffected sibs.
Because of the genotyping of multiple individuals in the
multiplex families (often including unaffected sibs), it was
possible to unambiguously determine the phase of chro-
mosomes included in both the affected and unaffected
categories. In addition to the nine haplotypes listed in
ﬁgure 1, we also combined haplotypes B and C into one
group (corresponding to the R702Wmutation) and hap-
lotypes E and F into one group (corresponding to the
1007fs mutation).
Odds Ratios and Statistical Signiﬁcance by Haplotype
Next, to determine whether each of the nine haplo-
types (listed in ﬁg. 1) was associated with the risk of
CD, the odds ratios (ORs) and x2 tests were calculated.
First, the patients with sporadic AJ ( chromo-np 72
somes) were compared with the AJ controls (np 492
chromosomes). For individual haplotypes B, C, D, E,
F, and I, ORs were calculated relative to haplotypes
AGH (i.e., the non–mutation bearing haplotypes),
combined by comparison of their frequencies in the case
group versus the control group; standard Pearson x2 tests
of the 2#2 table were calculated to assess signiﬁcance.
ORs for haplotypes G and H were calculated relative to
haplotype A only, to see if there was any difference in
risk between haplotypes G and H (which do not carry
mutations) and haplotype A.
For the multiplex families, analysis was based on the
transmission/disequilibrium test (TDT) (Spielman et al.
1993). ORs were calculated as the ratio of the number
of times a given haplotype X was transmitted versus not
transmitted to affected children of heterozygous parents.
For haplotypes B, C, D, E, F, and I (i.e., those carrying
mutations), the heterozygous parent could have A, G,
or H as the other haplotype. For haplotypes G and H,
the heterozygous parent had only A as the other hap-
lotype. Statistical signiﬁcance was calculated using Mc-
Nemar’s x2 test as , where T is the2(TNT) /(TNT)
number of times X was transmitted and NT the number
of times X was not transmitted (Spielman et al. 1993).
The AJ multiplex families and SOJ multiplex fami-
lies with CD were ﬁrst analyzed separately and then
combined.
Finally, a global estimate of ORs from the sporadic
and multiplex groups was obtained by Mantel-Haenszel
analysis, where, for each group, the natural log of the
ORs was calculated along with its variance, and a com-
bined log OR was obtained by taking the weighted sum,
the weight being the inverse variance. An overall (Man-
tel-Haenszel) x2 was also calculated as the square of the
combined log OR divided by its variance (Kleinbaum et
al. 1982).
Analysis of Mode of Inheritance
Next, the question of mode of inheritance was exam-
ined by estimating the risk of CD associated with carrying
one or two mutations. For this analysis, the mutation-
bearing haplotypes B, C, D, E, F, and I were grouped into
a single group (called “M”) to obtain adequate numbers,
and haplotypes A, G, and H were grouped into a single
mutation-free group (called “W”). For the sporadic cases
and controls, the ORs were estimated by counting the
number of individuals by diplotype (i.e., haplotype pair)
in the case versus control groups. Two ORs were calcu-
lated: OR1, based on diplotype MW versus WW, and
OR2.1, based on diplotypeMM versusMW.OR1 provides
an estimate of the relative risk for heterozygotes (i.e., bear-
ers of a single mutation), and OR2.1 provides an estimate
of the dosage effect (i.e., relative risk for bearers of two
mutations versus one mutation). The relative risk for
diplotype MM versus WW is then given by OR p2
.OR #OR1 2.1
The multiplex families were analyzed by TDT. Here,
OR1 was calculated from matings of MW#WW as the
ratio of the number of MW versus WW offspring and
frommatings of MW#MWas half the ratio of the num-
ber of MW versus WW offspring. OR2.1 was calculated
from matings of MM#MW as the ratio of the number
of MM versus MW offspring and from matings of
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MW#MW as twice the ratio of the number of MM
versus MW offspring. A combined estimate of the ORs
from the sporadic (case-control) and multiplex (TDT)
groups was obtained by Mantel-Haenszel analysis, sim-
ilar to that described above. In addition, 95% CIs on
the ORs were obtained from the log OR and its SE
(Kleinbaum et al. 1982).
Determination of CARD15 Mutations
and Chromosome 16q Linkage
Next, the degree to which the four mutations (R702W,
G908R, 1007fs, and N852S) could account for the ob-
served linkage evidence on chromosome 16 was deter-
mined on the basis of further analysis of the multiplex
AJ and SOJ families. First, the haplotypes were cate-
gorized into two groups, as described above: a mutation-
bearing group M (including haplotypes B, C, D, E, F,
and I) and a mutation-free group W (haplotypes A, G,
and H). The parents were then stratiﬁed into three het-
erozygous groups based on all SNPs tested plus the two
microsatellites: (1) group W1W2, constituting parents
carrying two distinguishable W haplotypes; (2) group
MW, constituting parents with one M and one W hap-
lotype; and (3) group M1M2, constituting parents with
two distinguishable M haplotypes. Within each hetero-
zygous parent class, we determined the number of af-
fected sib pairs that shared a W haplotype, shared an
M haplotype, or inherited different chromosomes from
that heterozygous parent. This analysis was stratiﬁed by
AJ versus SOJ, as well as by number of affected sibs in
the family (two, three, or four). For the larger families,
all possible affected sib pairs were formed. By this anal-
ysis, the overall degree of allele sharing in this region of
chromosome 16 was examined, as well as how much of
it was attributable to M chromosomes versus W chro-
mosomes. If the linkage evidence was fully explained by
the mutations included, then sharing of M chromosomes
should explain the overall excess (150%) observed.
Rare Variants
To determine whether additional rare variants could
further explain linkage evidence on chromosome 16, the
CARD15 gene was analyzed as described above. Rare
variants found in the AJ sporadic and AJ/SOJ multiplex
families were also genotyped in the AJ and SOJ controls
to determine their general population frequency. In the
multiplex families, identiﬁed rare variants were geno-
typed in the full family to determine whether the variant
was shared among affected family members.
Microsatellite Distribution on Haplotypes
To study the evolutionary history and relationship of
the various mutations and SNPs, the allele frequency
distributions were examined for the two microsatellites
(D16S3035 and D16S3136) on the nine SNP-based hap-
lotypes included in this study. For this analysis, all
independent chromosomes from the multiplex families
were included, whether carried by affected individuals
or not. This analysis focused on the larger, homogeneous
AJ sample, which included a total of 181 chromosomes.
Results
Common and Rare CARD15 Mutations/Variants in AJ
Patients with Familial and Sporadic CD
and in Controls
Of the 115 patients from the AJ multiplex families with
CD, 37.0% had one and 14.6% had two of the three
common CARD15 mutations. These mutations were de-
tected in 41.8% of their unaffected parents (34.1% had
one mutation and 7.7% had two) and in 40% of their
unaffected sibs (all with one mutation). Among the 36 AJ
patients with sporadic CD, 27.7% of patients had one
and two patients (5.5%) had two (R702W/R702W and
R702W/G908R) of the common mutations. In contrast,
16.2% and 2.0%of the 246 unrelated AJ healthy controls
had one or two of these mutations, respectively. The com-
bined allele frequency of the three mutations was 0.101
in AJ controls, 0.208 in patients with sporadic CD, and
0.301 in patients from multiplex families with CD (table
2).
Common and Rare CARD15 Mutations/Variants in SOJ
Patients with Familial CD and in Controls
Of the 21 familial SOJ patients with CD, 23.8% and
33.3% inherited two or one of the common mutant al-
leles, respectively, and 52.6% of their parents and 38.4%
of their unaffected sibs had one of the commonCARD15
mutations. No parent or unaffected sib carried two mu-
tations. The combined allele frequency for the three com-
mon mutations was 0.345 among the SOJ patients from
multiplex families with CD, whereas the combined mu-
tation frequency in the SOJ healthy subjects was 0.054.
It should be kept in mind that both the SOJ patients
with CD and the healthy subjects were of heterogeneous
ethnic Sephardi and Oriental (Mediterranean) origin.
The proportion of SJ and OJ alleles among these controls
was about 1:1.
Haplotype Frequencies
Haplotype analysis of the three common mutations
and the common polymorphism P268S revealed six dif-
ferent haplotypes in the AJ and SOJ families with CD
(ﬁg. 1). These included haplotypes A (no variants), B
(P268S/R702W), C (P268/R702W), D (P268S/G908R),
E (P268S/1007fs), and H (P268S alone). Detection of
the IVS8158 polymorphism and rare variants increased
the number of haplotypes to nine. The additional hap-
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Table 2
Haplotype Frequencies by Group
HAPLOTYPE
FREQUENCY IN AJ GROUP FREQUENCY IN SOJ GROUP
Control
( )np 492
Multiplex
Unaffecteda
( )np 52
CD
Sporadic
( )np 72
CD Familialb
Control
( )np 164
Multiplex
Unaffecteda
( )np 8
CD
Familialb
( )np 32
Total
( )np 143
Central Europe
( )np 50
Eastern Europe
( )np 67
A .705 .712 .694 .559 .420 .597 .709 1.0 .563
B .012 .000 .056 .028 .040 .030 .018 .000 .094
C .016 .019 .014 .028 .000 .045 .000 .000 .000
BC (702W) .028 .019 .069 .056 .040 .075 .018 .000 .094
D (908R) .043 .038 .083 .112 .200c .075 .036 .000 .188
E .014 .019 .000 .077 .105 .060 .000 .000 .063
F .016 .038 .056 .056 .107 .030 .000 .000 .000
EF (1007fs) .030 .058 .056 .133 .200 .090 .000 .000 .063
I (852S) .012 .019 .014 .035 .040 .045 .018 .000 .000
G .075 .038 .069 .063 .040 .090 .110 .000 .063
H .106 .115 .014 .042 .060 .030 .110 .000 .031
Common mutationsc .101 .115 .208 .301 .440d .240 .054 .000 .345
NOTE.—n p number of chromosomes.
a Independent chromosomes carried by no affected individual in family.
b Independent chromosomes carried by at least one affected individual in family.
c 702W, 908R, and 1007fs.
d Signiﬁcant ( ) difference between Central Europe and Eastern Europe.P ! .05
lotypes were F (P268S/M863V/1007fs), G (P268S/
IVS8158), and I (P268S/N852S) (ﬁg. 1). The recently
reported IVS8158 polymorphism (Sugimura et al. 2003)
was present on all the haplotypes (ﬁg. 1), with the ex-
ception of haplotypes A, D, and H.
Although prior studies have focused singly on the
702W mutation, we found it to be associated with two
different haplotypes (B and C) on the basis of the presence
or absence, respectively, of the P268S variant. Similarly,
we found the 1007fs mutation to be associated with two
different haplotypes on the basis of the absence or pres-
ence, respectively, of the M863V variant. Haplotype fre-
quencies were calculated on the basis of independent chro-
mosome numbers, as explained in the “Subjects and
Methods” section. Haplotype and mutation frequencies
in the “unaffected chromosome” group from the AJ mul-
tiplex families were slightly higher than but similar to
those found in the AJ control group (table 2), ranging
from 1.2% (for N852S) to 2.8% and 3.0% (for R702W
and 1007fs) to 4.3% (for G908R). Although the allele
frequencies are lower for R702W and G908R, the com-
bined mutation frequency for mutations R702W,G908R,
1007fs, and N852S was 0.134 in the multiplex “unaf-
fected chromosome” group and was 0.113 in the AJ con-
trol group. Even when the newly identiﬁed N852S se-
quence variant was excluded, the frequencies of the other
three common mutations combined were somewhat
higher than have been reported for other white popula-
tions (see the “Discussion” section). All four mutations
were found at increased frequency in both the AJ sporadic
group and the AJ multiplex group, but the frequencies
were generally more increased in the multiplex group. For
the sporadic group, the frequencies ranged from 1.4%
(for N852S) to 5.6% (for 1007fs) to 6.9% (for R702W)
to 8.3% (for G908R). For the multiplex group, the cor-
responding frequencies were 3.5%, 13.3%, 5.6%, and
11.2%. For the four mutations combined, the overall fre-
quency was 22.2% for the sporadic group and 33.6% for
the multiplex group. Most of these mutations appeared
to be similarly elevated in frequency in the SOJ group
(with the exception of N852S), ranging from 6.3% (for
1007fs) to 9.4% (for R702W) to 18.8% (for G908R),
for a total mutation frequency of 34.5%.
The total haplotype frequency for mutation-bearing
chromosomes was signiﬁcantly elevated ( ) in AJP ! .05
patients with CD in the multiplex families with Central
European ancestry (0.440), compared with those from
Eastern European families (0.240). The difference was
due to the excess frequencies of both the 908R and
1007fs mutations in the former group, although only
the frequency difference for 908R was formally signif-
icant ( ). This difference was consistent with theP ! .05
previously reported elevated frequency of CD in AJ in-
dividuals with ancestry from Central as opposed to East-
ern Europe (Roth et al. 1989a, 1989b; Zlotogora et al.
1990; Yang et al. 1993) . The total mutation frequency
in the patients with CD from families of SOJ origin was
comparable to that of the AJ families, although the 908R
mutation was found at somewhat higher frequency and
the 1007fs mutation was found at a somewhat lower
frequency. However, the 908R mutation was found at a
comparable frequency in the AJ and SOJ healthy groups.
On the other hand, the 1007fs mutation also was found
at lower frequency (absent) in the SOJ controls, sug-
gesting that this mutation is less frequent in the Medi-
terranean/Middle East than in Central/Eastern Europe.
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Risks Associated with Individual Mutations
and Haplotypes
As suggested by the results in table 2, all mutations
showed signiﬁcant association with CD risk (table 3).
For the sporadic case-control analysis, ORs were ele-
vated for all mutations, ranging from 1.30 to 2.78, but
were signiﬁcant only for R702W, G908R, and 1007fs.
The OR for all mutations combined was 2.22 ( ).P ! .01
For the TDT analysis based on the multiplex families
(AJ and SOJ combined), again, all ORs were elevated
and signiﬁcant and somewhat higher than for the spo-
radic case-control analysis, with values of 2.27–7.00.
For all mutations combined, the OR was 3.05 (P !
). Examination of all groups combined in the Man-.001
tel-Haenszel analysis suggested that all mutations have
a similar degree of elevated risk based on the OR, which
ranged from 2.87 (for R702W) to 2.26 (for G908R) to
3.03 (for 1007fs) to 3.06 (for N852S). The ORs for
haplotypes B and C, both of which carry the R702W
mutation, appeared to be discrepant, with a much higher
OR for haplotype B than for C. Although it is possible
that either the P268S variant or another variant in link-
age disequilibrium with it inﬂuences—in cis with the
R702W mutation—the risk of CD, it is also possible
that the observed difference is simply a matter of chance,
owing to the low population frequency of these haplo-
types. The higher observed ORs for the multiplex group
compared with the sporadic group was not unexpected,
depending on the mode of inheritance, as we detail be-
low. Table 3 also indicates a signiﬁcantly decreased risk
for haplotype H in the case-control analysis, but a de-
creased risk of only marginal signiﬁcance is indicated in
the combined Mantel-Haenszel analysis. This protective
effect of the P268S variant alone has not been reported
previously and requires further independent study to de-
termine whether this observation is replicable.
Risks for Single versus Double Dose
ORswere calculated to estimate the relative risk ofMW
versus WW (OR1) and MM versus MW (OR2.1), where
M represents the group of mutation-bearing haplotypes
(B, C, D, E, F, and I), and W represents the wild-type or
mutation-free haplotypes (A, G, and H). In the AJ spo-
radic CD group, there were 23 WW, 10 WM, and 3 MM
genotypes, whereas, in the control group, there were 195
WW, 46 WM, and 5 MM genotypes. For this analysis,
the Hardy-Weinberg expected frequencies (193.18 for
WW, 49.63 for WM, and 3.19 for MM) were used to
obtain more-precise estimates. From the AJ sporadic case-
control study, OR1 is estimated as 1.69 and OR2.1 as 4.67.
The TDT analysis of the combined AJ and SOJ multiplex
families had similar values. Matings of WM#WW re-
sulted in 12 WW and 18 WM offspring; matings of
WM#WM had 0 WW, 8 WM, and 15 MM offspring;
andMM#WMmatings had 2WMand 6MMoffspring.
OR1 was estimated as 1.83, and OR2.1 was estimated as
3.50. The Mantel-Haenszel estimate for the case-control
and TDT analyses combined was 1.78 for OR1 and 3.71
for OR2.1, both of which are statistically signiﬁcant (table
A [online only]). These results indicate both an increased
risk for heterozygotes—that is, those carrying a single
CARD15 mutation—and a dosage effect, with a signiﬁ-
cantly increased risk for those carrying two mutations
versus one. These results also provide the explanation for
the somewhat increased ORs observed for single haplo-
types in the TDT analysis of multiplex families versus the
case-control analysis of the sporadic cases (table 3). Anal-
ysis of ORs for single haplotypes is based on an average
of ORs for one-dose and two-dose cases. The sampling
of multiplex sibships gave rise to a higher proportion of
affected individuals in those families carrying two mu-
tations compared with the sporadic cases, leading to a
higher estimated OR for the former. When analysis was
stratiﬁed by dose, the ORs for the sporadic cases and
multiplex families were not different.
CARD15 Mutations versus Chromosome 16q Linkage
A major question regarding CARD15 is whether the
identiﬁed mutations can explain the linkage evidence in
this region of chromosome 16q in multiplex families
with CD. Our collection of 50 AJ and 10 SOJ multiplex
families provided the opportunity to address this ques-
tion. We investigated the distribution of allele sharing
by affected sib pairs stratiﬁed by the heterozygous parent
genotype and the number of affected sibs (table B [online
only]). The overall allele sharing in the entire sample
was 57.8% (74 shared and 54 unshared), comparable
to prior linkage studies in this region (Cavanaugh 2001).
Sharing was greater in the AJ families (61.8%; 63 shared
and 39 unshared) than in the SOJ families (42.3%; 11
shared and 15 unshared), although the number of SOJ
families was small ( ). Also noticeable was the2x p 3.1
difference in allele sharing for affected sib pairs (60.7%)
versus the larger families (trios and quads), where shar-
ing was 51.3% (20 shared versus 19 unshared) ( 2x p
). Although the allele sharing differences between AJ1.0
and SOJ and between pairs versus trios plus quads were
not signiﬁcant, the latter result was consistent with the
observation of greater sharing in affected pairs than in
larger sibships from a pooled analysis of a large number
of families with CD (Cavanaugh 2001).
When we considered allele sharing by parental ge-
notype, overall sharing was slightly higher from MW
parents (61.7%), where 26 of the 29 shared alleles were
M, than from W1W2 parents, where the overall sharing
was 54.8% (40 shared and 33 unshared). When we con-
sidered affected sib pairs only, however, we found similar
sharing from MW and W1W2 parents, at 61.0% and
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60.0%, respectively. This observation suggests that the
four identiﬁed mutations in CARD15, despite being pos-
itively associated with risk of CD, do not fully explain
the linkage evidence on chromosome 16q.
It is interesting that there is also a substantial differ-
ence in the distribution of parental genotypes for the
pairs versus the trios plus quads. For the pairs, 40 par-
ents are W1W2 heterozygotes, 41 are MW heterozygotes
and 8 are M1M2 heterozygotes. In contrast, for the trios
plus quads, 9 parents are W1W2 heterozygotes compared
with 2 who are MW and 0 who are M1M2 . Thus, for
the sib pairs, there are 57 M haplotypes (32.0%) out of
178 total among the parents, whereas, for the trios plus
quads, there are 2 M haplotypes (9.1%) out of 22 total.
This result counters what might have been expected—
namely, an increase in the number of M haplotypes
among the parents of the larger sibships—and suggests
the possibility of genetic heterogeneity, whereby the
larger sibships are segregating for another gene unrelated
to CARD15.
Additional Variants
Because it appeared that the three previously identiﬁed
mutations in CARD15 (R702W,G908R, and 1007fs) and
the newly identiﬁedN852S did not fully explain our chro-
mosome 16q linkage evidence, we searched for additional
rare variants on the “mutation-free” haplotypes (A, G,
and H), as well as for common variants. In the 43 AJ
patients with familial CD and 35 AJ patients with spo-
radic CD who had only one or none of the common
CARD15 mutations, DHPLC heteroduplex analysis and
sequencing revealed that all had a novel or previously
reported variant (table 4). These included the novel
changes D113N, D357A, and N852S and the previous-
ly reported variants L248R, E441K, A612T, M863V,
A918D, 5′-UTR-33TrG, 5′-UTR-15TrA, R459R,
R587R, A611A, IVS410ArC, V955I (Lesage et al.
2002), and IVS8158 (Sugimura et al. 2003). Of the six
SOJ patients with familial CD who had only one or none
of the common mutations, four had rare CARD15 var-
iants, including two novel (I363F and L550V) and two
previously reported (R703C and A612T) changes (Lesage
et al. 2002) (table 4). These changes occurred in four
unrelated SOJ subjects with CD. The rare amino acid
substitutions (D113N, L248R, D357A, I363F, E441K,
L550V, A612T, R703C, and A918D) all occurred with
the P268 allele (i.e., on haplotype A) (table 4). We ex-
amined the segregation pattern of the seven rare amino
acid substitutions identiﬁed in the multiplex families, one
of which occurred in two different families and another
of which occurred in three families (table 4). In four of
seven informative affected sib pairs, the identiﬁed variant
was shared between the affected sibs, and in the other
three it was not shared. Thus, these additional rare var-
iants cannot be shown (by statistical evidence) to be dis-
ease predisposing, and they do not provide an explanation
for the residual linkage evidence observed on chromo-
some 16q in our study.
Evolutionary History of Haplotypes
The presence of information on the two microsatellite
loci D16S3035 and D16S3136 on haplotypes A–I al-
lowed consideration of some historical and evolutionary
aspects of these chromosomes. This analysis focused on
the much larger and homogeneous collection of AJ chro-
mosomes, although the results were not substantially
different for the SOJ group. On the basis of the presence
of the various SNPs, haplotype H could have been de-
rived from haplotype A by a single mutation (P268S).
Further single changes occurred on haplotype H to give
rise to haplotype D (mutation G908R) and haplotype
G (variant IVS8). Subsequent single mutations then oc-
curred on haplotype G to give rise to haplotype I (variant
N852S), haplotype E (mutation 1007fs), and haplotype
B (mutation R702W). Haplotype E sustained another
single variant (M863V) to give rise to haplotype F. Hap-
lotype C, without the P268S variant but carrying both
R702W and IVS8, may have arisen through recombi-
nation of haplotype B with an A haplotype. This is the
only haplotype requiring an ancestral recombination or
gene conversion event to explain its existence. The mi-
crosatellite data in table 5 support such a model. Hap-
lotype H has a similar allele frequency distribution to
that of haplotype A, suggesting that the P268S change
was a relatively early event. Haplotype D, however,
shows a distinct pattern at D16S3136, carrying the 204
allele at high frequency, which suggests a relatively more
recent event for the G908R mutation. Haplotype G also
shows a somewhat altered pattern from haplotype A
(again a high frequency of the 204 allele at D16S3136).
Haplotypes I and E, representing single mutation events
on haplotype G, both show a very distinctive pattern,
with haplotype I carrying a 268 allele at D16S3035 (rare
on haplotype G) and haplotype E carrying a 264 allele
at D16S3035 (also rare on haplotype G). Haplotype
F shows an identical pattern to that of haplotype E
at D16S3035 and a more restricted distribution at
D16S3136 than haplotype E, consistent with its deri-
vation from haplotype E. Haplotypes B and C also show
a distinctive and similar pattern, with the predominance
of the 202 allele at D16S3136. All the mutation-bearing
haplotypes show a much narrower range of microsat-
ellite allele sizes than the common A haplotype, consis-
tent with their recent origin.
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Table 5
Microsatellite Allele Distribution On Haplotypes In AJ and SOJ Individuals
HAPLOTYPE (SNPS)
AND ETHNICITY
NO. OF
CHROMOSOMES
FREQUENCY OF D16S3035 ALLELE FREQUENCY OF D16S3136 ALLELE
264 266 268 270 198 200 202 204 206 208 210
A:
AJ 107 .11 .81 .06 .02 .07 .17 .33 .32 .09 .03 .00
SOJ 22 .05 .86 .05 .05 .09 .05 .50 .18 .14 .05 .00
H (268S):
AJ 11 .00 1.0 .00 .00 .00 .00 .45 .45 .10 .00 .00
SOJ 1 .00 1.0 .00 .00 .00 .00 1.0 .00 .00 .00 .00
D (268S908R):
AJ 18 .06 .89 .06 .00 .00 .00 .11 .83 .06 .00 .00
SOJ 6 .00 .83 .17 .00 .00 .00 .17 .83 .04 .00 .00
G (268SIVS8):
AJ 10 .00 .90 .00 .10 .00 .11 .11 .67 .00 .11 .00
SOJ 2 .00 1.0 .00 .00 .00 .00 .00 1.0 .00 .00 .00
I (268SIVS8852S):
AJ 6 .00 .00 1.0 .00 .00 .00 .00 .00 .00 .00 1.0
SOJ 0 … … … … … … … … … … …
E (268SIVS81007fs):
AJ 11 1.0 .00 .00 .00 .09 .00 .09 .73 .09 .00 .00
SOJ 2 1.0 .00 .00 .00 .00 .00 .00 1.0 .00 .00 .00
F (268SIVS81007fs 863V):
AJ 11 1.0 .00 .00 .00 .00 .00 .00 1.0 .00 .00 .00
SOJ 0 … … … … … … … … … … …
B (268SIVS8702W):
AJ 3 .00 1.0 .00 .00 .00 .00 1.0 .00 .00 .00 .00
SOJ 3 .00 .67 .00 .33 .00 .00 1.0 .00 .00 .00 .00
C (IVS8702W):
AJ 4 .25 .75 .00 .00 .00 .00 .75 .25 .00 .00 .00
SOJ 0 … … … … … … … … … … …
Discussion
Recently, a CD susceptibility gene at the IBD1 locus on
chromosome 16 was identiﬁed as the CARD15/NOD2
gene. To date, three common (R702W, G908R, and
1007fs) and 125 rare CARD15 variants have been iden-
tiﬁed (Hampe et al. 2001; Hugot et al. 2001; Ogura et
al. 2001; Lesage et al. 2002). The results presented here
conﬁrm the association of the three common mutations
with CD in both AJ and SOJ patients. In the unaffected
controls, the total allele frequency for the three muta-
tions combined in the Ashkenazi population (10.1%)
was higher than in the (mixed Mediterranean/Middle
Eastern) Sephardi/Oriental group (5.4%). This was also
true for all three mutations individually, but it was par-
ticularly the case for the 1007fs mutation. On the other
hand, the same was not true in the CD cases, for which
the overall allele frequency was slightly higher in the
SOJ multiplex group (34.5%) than in the AJ multiplex
group (30.1%). Similarly, other studies of AJ patients
with CD have consistently found an increased frequency
of the G908R mutation compared with non-Jewish pop-
ulations, but this has not been true for the other two
mutations (Zhou et al. 2002; Bonen et al. 2003; Sugi-
mura et al. 2003).
The prevalence of CD in the Ashkenazim is unusually
high, having a two- to fourfold greater frequency than
in non-Jewish European or North American whites
(Roth et al. 1989a, 1989b; Sonnenberg et al. 1991; Kur-
ata et al. 1992; Probert et al. 1993; Yang et al. 2001).
Among AJ patients with CD, a higher prevalence has
been noted in those with origins from Central Europe
than in those from Russia and Poland (Roth et al.
1989a, 1989b; Zlotogora et al. 1990; Yang et al. 1993).
Consistent with this latter observation, in the multiplex
AJ families with CD studied here, there also was a
higher frequency of the three common CARD15 mu-
tations in AJ patients with origins in Central Europe
(44.0%) than in those from Eastern Europe (24.0%).
The excess frequency was observed primarily for the
G908R and 1007fs mutations.
One potentially interesting contributor to differences
between AJ CD and non-Jewish CD may be mutation
R702W. In AJ individuals, this mutation was present
on two different haplotype backgrounds, one with the
P268S allele (haplotype B) and the other with the P268
allele (haplotype C). The P268S allele was completely
associated with the other two mutations G908R and
1007fs. In our study, an increased risk was found for
the R702W allele only in the context of haplotype B
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(with P268S) and not with haplotype C (with P268)
(table 3). Also, haplotype B occurred only in AJ patients
with CD whose ancestry was from Central Europe.
Other studies of non-Jewish CD have reported only hap-
lotype B. It will be interesting to determine, in other
studies of AJ patients with CD, whether this back-
ground effect of P268S on R702W expression can be
conﬁrmed.
Another important question is whether CARD15 is
the only CD susceptibility gene on chromosome 16. This
question is addressed by considering the degree to which
identiﬁed CARD15 mutations explain the linkage evi-
dence observed in multiplex families. The overwhelming
answer to this question now appears to be that CARD15
does not fully explain the linkage evidence. At least ﬁve
studies now show that CD affected sib pair families that
segregate none of the three common CARD15 muta-
tions still demonstrate linkage on chromosome 16 (Hu-
got et al. 2001; Hampe et al. 2002; Cavanaugh et al.
2003; Sugimura et al. 2003; present study). In our study,
the mean allele sharing in families with CARD15 mu-
tations was 34/55 (61.8%), versus 40/73 (54.8%) in
families without CARD15 mutations.
It also appears that the residual allele sharing ob-
served on chromosome 16 cannot be explained by ad-
ditional CARD15 variants. In our study, we employed
DHPLC heteroduplex analysis and sequencing of the
CARD15 gene in 43 AJ patients with familial CD and
34 AJ patients with sporadic CD who had only one or
no CARD15 mutation. Among these patients, three
novel (D113N, D357A, and N852S) and several pre-
viously reported sequence changes were identiﬁed, in-
cluding L248R, E441K, A612T, M863V, and A918D.
The new variants D113N, D357A, and N852S were in
the CARD1, NBD, and the fourth LRR domain of
CARD15, respectively. Of these, N852S, which is a con-
served amino acid in the mouse CARD15 gene, was
found in six AJ families with CD and in one AJ patient
with sporadic CD, whereas the conserved L248R and
A612T were each detected in two AJ families with CD.
In six SOJ subjects with CD without two common
CARD15 mutations, DHPLC analysis revealed two pre-
viously reported variants, R703C and A612T, and two
novel variants, I363F and L550V. Both novel variants
were in the NBD domain of CARD15, L550V being
conserved in mouse. However, in AJ multiplex families
with CD, although moderately convincing evidence was
found for variant N852S (with a frequency of ∼1% in
the AJ population) to be disease predisposing, excess
allele sharing was not found for the other rare variants.
Also, support for another recently reported high-fre-
quency variant (IVS158CrT) being associated with
CD (Sugimura et al. 2003) was not found. None of the
additional reported variants, either in this or in previous
studies, was able to fully explain the residual linkage
evidence observed on chromosome 16.
Of note, both the linkage evidence and presence of
CARD15 mutations were related to the number of af-
fected individuals in the family. In this study, both the
linkage evidence (mean allele sharing) and the presence
of CARD15 mutations decreased in families with three
or more CD cases versus those with two. The pooled
linkage analysis also found decreased allele sharing in
families with three or more CD affected sibs (Cavan-
augh 2001). According to any simple model of inheri-
tance, the frequency of CARD15 mutations should in-
crease with the number of CD cases in the family. The
observed pattern raises the likelihood of genetic com-
plexity in the form of genetic heterogeneity. The evi-
dence supports both an additional susceptibility locus
on chromosome 16 as well as another locus (or loci)
elsewhere.
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